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PB 445 | Use of a Synthetic Collagen to 
Monitor Platelet Function in Patients Receiving 
Dual Antiplatelet Therapy
W. Jeske, V. Escalante, W. Klein, C. Kartje, J. Walenga, 
M. Bakhos
Loyola University Medical Center, Cardiovascular Research Institute, Maywood, 
United States
Background: Patients with coronary artery disease (CAD) are treated 
with aspirin and a P2Y12 antagonist to prevent myocardial infarction 
or stent thrombosis. Variable clinical response to both types of agents 
has been reported. Existing assays to identify sub-optimal response to 
anti-platelet therapy do not meet reported medical needs.
Aims: To characterize the utility of a synthetic collagen (SynC) to mon-
itor platelet function in patients on dual-antiplatelet therapy.
Methods: Blood samples from healthy individuals (n=5) and CAD 
patients treated with clopidogrel (75-600 mg) with or without as-
pirin (75-325 mg) (n=51) were centrifuged to produce plasmas for 
aggregometry studies (PAP 8E, Bio/Data Corp. Horsham, PA). The ag-
gregation response to 20 μM ADP, 500 μg/ml arachidonic acid and 
190 μg/ml Type 1 biologic collagen was compared to that induced by 
SynC (2-200 ng/ml; JNC Corp., Yokohama, Japan). The aggregation 
response was characterized in terms of % aggregation, slope and AUC.
Results: Using plasmas from healthy individuals and CAD patients, 
two lots of SynC produced a concentration-dependent aggregation re-
sponse over a concentration range of 16 to 128 ng/ml. Patients treated 
with 81 mg aspirin and 75 mg clopidogrel (33 of 51 patients) were strat-
ified into two groups based on their % aggregation response to SynC, 
using the median % aggregation as the cut point. While the two groups 
had a distinct response to SynC, the median responses to ADP, arachi-
donic acid and biologic collagen were nearly the same and there was 
a strong overlap between the responses to these agonists in the two 
sub-groups. This is most evident at the lower concentrations of SynC.
Conclusions: SynC-induced platelet aggregation may identify sub-
groups of patients with sub-optimal response to dual antiplatelet 
therapy that go undetected with traditional platelet agonists. Studies 
to clarify why biologic and synthetic collagens have different sensitivi-
ties to aspirin and clopidogrel are warranted. 
PB 446 | Stability of TGA Parameters in 
Patients Treated with Anticoagulants Using the 
Fully Automated ST-Genesia System
J. Douxfils1, J.-B. Nicolas2, A.-S. Larock3, B. Devalet4, Y. 
Vandermeeren5, V. Gérard6, M. Guldenpfennig7, K. De Fays5, 
J. Baudar7, F. Mullier7
1University of Namur, Department of Pharmacy, Namur, Belgium, 2CHU UCL 
Namur, Department of Internal Medicine, Yvoir, Belgium, 3CHU UCL Namur, 
Department of Pharmacy, Yvoir, Belgium, 4CHU UCL Namur, Department of 
Hematology, Yvoir, Belgium, 5CHU UCL Namur, Department of Neurology, Yvoir, 
Belgium, 6CHU UCL Namur, Department of Emergency, Yvoir, Belgium, 7CHU UCL 
Namur, Hematology Laboratory, Yvoir, Belgium
Background: Current thrombin generation assay (TGA) systems are 
semi-automated with samples tested in batch. Thus, the method lacks 
automation and standardization for homogeneity in results from study 
to study. TGA may be more informative than plasma concentration to 
assess the intensity of anticoagulation in a particular individual. A new 
automated and standardized TGA assay (i.e: ST-Genesia) has been re-
cently developed by Stago.
Aims: To assess if TGA results in healthy subjects and patients treated 
by DOACs (dabigatran, rivaroxaban, apixaban), vitamin K antagonist 
(acenocoumarol) or LMWH (enoxaparin) are stable along time on sam-
ples stored at around -80°C during 10 months.
Methods: 6 healthy individuals and 30 samples of patients treated 
with anticoagulants were planned to be collected according to stand-
ard pre-analytical conditions. Samples were taken at peak and antico-
agulant activity was measured according to current recommendations. 
Each sample were planned to be tested fresh (D0) and after storage at 
-80°C during 1 day (D1), 1 month (M1), 2 months, 3 months, 6 months, 
9 months and 10 months. Impact of freezing (D1 vs D0) was to be as-
sessed through paired-sample analysis (Student or Wilcoxon test) and 
stability through evaluation of trends overtime vs D1.
Results: Currently 6 healthy subjects, 7 apixaban, 3 dabigatran, 6 rivar-
oxaban, 5 VKA and 6 LMWH patients were included. Only results for 
D0, D1 and M1 are currently available. Table 1 summarizes, the mean 
difference relative to D0 or D1 and the range of relative deviations. 
Conclusions: Freezing slightly affects all TG parameters. Once plas-
mas are frozen, TG parameters are also slightly influenced during the 
first month of storage. As it is frequently impossible to ensure that 
storage duration of samples is strictly equivalent throughout a study 
on a plasma bank, working with fresh samples would help in avoiding 
the outliers observed. This demonstrates the utility of a fully automa-
tized TGA analyzer that could be integrated in the routine lab. 
F I G U R E  1
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PB 447 | First European Evaluation of 
ClarityCor Plasma Set for Instrument to 
Instrument Reproducibility Assessment
M.M.W. De Sloovere, K.M. Devreese
Ghent University Hospital, Coagulation Lab, Department of Laboratory Medicine, 
Ghent, Belgium
Background: In Accreditation context, labs have to manage reproduc-
ibility between instruments.
To perform such testing, the lab can archive patient samples spanning 
the reportable range or can purchase pre-assayed validation plasma 
sets from commercial suppliers. 
In this context, Stago (Asnières, France) has developed the ClarityCor 
(CC) Plasma Set, a set of frozen plasmas enabling to verify the correla-
tion between different coagulation analysers.
Aims: Evaluation of CC Plasma Set to assess between-instrument re-
producibility in comparison to locally selected frozen plasma samples.
Methods: One CC Plasma Set (n=30 for PT, INR, aPTT and Fibrinogen 
(Fibr) + n=5 for INR across the reportable range) was used for each 
instrument in the lab (Figure 1). In addition, citrated patient plasmas 
were collected. Method comparison to the mean of all analysers was 
done by Passing-Bablok (PB) regression and Bland-Altman (BA) anal-
ysis. Comparison was made between CC Plasma and patient sample 
datasets.
Results: Rank correlations (Rs) were between 0.967 and 0.999. PB 
slopes revealed no proportional bias for PT(sec) and INR of patient 
samples and CC Plasma Set except for STAR-MAX. 2/5 and 3/5 ana-
lysers showed concordant slope results between both data sets for 
aPTT and fibrinogen.. The %mean difference was ≤5% and ≤3.7% for 
all analyser/parameter combinations as compared to the mean and 
between datasets respectively (figure 1). All manufacturer‘s criteria 
were met (Rs>0.95, proportional(slope:0.9< x< 1.1) and systematic 
bias(BA %bias: 5-10%)).
Conclusions: Between instrument evaluation with CC Plasma Set re-
sults in sufficient data across the measuring range of PT, INR, aPTT 
and Fibrinogen. No major deviations were noted between frozen sam-
ples and CC Plasma Set. Given the advantages of sufficient plasma 
volume for all 3 parameters on a multitude of analysers and no need 
for time-consuming selection of suitable patient samples, the CC 
Plasma Set is a good alternative for local patient samples to evaluate 
between-instrument reproducibility. 
PB 448 | Comparison of Activated Clotting 
Time Measured by I-STAT, Sonoclot and 
ACTPlus and Correlation with Anti-Xa during 
Cardiopulmonary Bypass Procedures
S. Vandendriessche1, F. De Somer2, H. Laverge1, K. Devreese1
1University Hospital Ghent, Clinical Biology, Ghent, Belgium, 2University Hospital 
Ghent, Cardiac Surgery, Ghent, Belgium
Background: Activated clotting time (ACT) is used to monitor antico-
agulation therapy with high heparin concentrations.
 Lag time (min) Peak Height (nM) Time to Peak (min) ETP (nM.min)
 D1 vs D0 M1 vs D1 D1 vs D0 M1 vs D1 D1 vs D0 M1 vs D1 D1 vs D0 M1 vs D1
Healthy 
subjects
Mean diff. 
(range)
-1% (-15 to 
11%)
-8% (-12 to 
4%)
-8% (-12 to 4%) 5% (0 to 7%) -1% (-19 to 
20%)
-7% (-10% 
to -3%)
-6% (-27% to 
24%)
-2% (-8% to 
3%)
Apixaban Mean diff. 
(range)
0% (-10% to 
12%)
1% (-20% to 
33%)
15% (-4% to 
28%)
-2% (-12% 
to 9%)
-4% (-12% to 
6%)
1% (-8% to 
15%)
2% (-9% to 
7%)
0% (-23% 
to 18%)
Dabigatran Mean diff. 
(range)
-10% (-14% 
to -4%)
-10% (-19% 
to 2%)
2% (-3% to 6%) 3% (-2% to 
8%)
-7% (-12% to 
1%)
-9% (-16% 
to -2%)
2% (1% to 
3%)
-6% (-8% to 
-3%)
Rivaroxaban Mean diff. 
(range)
-7% (-11% to 
-4%)
-6% (-12% 
to 7%)
13% (-5% to 
25%)
-1% (-14% 
to 16%)
-7% (-12% to 
-3%)
-4% (-12% 
to 2%)
6% (-9% to 
20%)
-2% (-6% to 
5%)
VKA Mean diff. 
(range)
-1% (-6% to 
1%)
-3% (-13% 
to 2%)
1% (-4% to 5%) -1% (-11% 
to 10%)
-1% (-4% to 
2%)
-1% (-11% 
to 5%)
3% (-3% to 
11)
-2% (-16% 
to 8%)
LMWH Mean diff. 
(range)
-1% (-9% to 
6%)
-9% (-20% 
to 3%)
15% (-5 to 69%) 0% (-26% to 
18%)
1% (-8% to 
10%)
-6% (-15% 
to 3%)
14% (-1% to 
54%)
-3% (-18% 
to 17%)
T A B L E  1 Stability of TGA parameters after 1 day and 1 month storage at -80°C.
F I G U R E  1 Overview of %mean bias comparing a single analyser 
(3 STAR Evolutions [A,B,C],STAR-MAX,STAC-MAX) with the mean of 
all analysers for routine parameters
